期刊文献+

JAK2 V617F阳性慢性中性粒细胞白血病一例并文献复习

原文传递
导出
摘要 目的分析慢性中性粒细胞白血病的临床特点和诊断,提高对该病的认识。方法报告一例慢性中性粒细胞白血病的临床特点、治疗及预后,并进行文献复习。结果该患者以巨脾,显著白细胞升高为临床特征;血常规中性粒细胞比例大于80%;JAK2/V617F阳性;bcr-ablp190阴性,bcr—ablp210阴性,bcr—ablp230阴性;N—ALP阳性率89%,积分275。对HA方案及羟基脲维持化疗敏感。随访27个月患者病情平稳。结论辅助检查对于明确诊断慢性中性粒细胞白血病至关重要,关键在于排除相类似的几种骨髓增殖性肿瘤和类白血病反应。
作者 高大 肖镇
出处 《白血病.淋巴瘤》 CAS 2011年第3期181-181,190,共2页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献10

  • 1Elliott MA, Dewald GW, Tefferi A, et al. Chronic neutrophilie leukemia (CNL): a clinical, pathologic and cytogenetic study. Leukemia, 2001, 15: 35-40.
  • 2Elliott MA. Chronic neutrophilic leukemia: a contemporary review. Curr Hematol Rep, 2004, 3: 210-217.
  • 3陈石,李德高.慢性中性粒细胞白血病诊断探讨[J].临床血液学杂志,2007,20(3):141-142. 被引量:4
  • 4Harris NL, Jaffe ES, Diebold J, et al. The world health organization classification of neoplasms of the hematopoietie and lymphoid tissues: report of the clinical advisory committee meeting-airlie house, virginia, november, 1997. Hematol J, 2000, 1: 53-66.
  • 5Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 2008, 22: 14-22.
  • 6袁利亚,李红,陈国安,纪德香,高琳琳,戎吉平,俞火.JAK2V617F基因突变在骨髓增生性疾病中的发生率及其临床意义[J].浙江大学学报(医学版),2010,39(2):202-206. 被引量:14
  • 7梅丽娜,王季石,卢英豪,李建勇.141例慢性骨髓增生性疾病中JAK2基因V617F点突变的研究[J].临床血液学杂志,2009,22(3):244-249. 被引量:8
  • 8Baxter E J, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 2005, 365: 1054-1061.
  • 9Sakka V, Tsiodras S, Giamarellos-Bourboulis E J, et al. An update on the etiology and diagnostic evaluation of a leukemoid reaction. Eur J Intern Med, 2006, 17: 394-398.
  • 10曹鹏飞,刘友生,柳永和.中性粒细胞碱性磷酸酶在骨髓增生性疾病诊断及疗效观察中的价值[J].白血病.淋巴瘤,2006,15(6):435-437. 被引量:5

二级参考文献39

  • 1丛玉隆,冉宝春,张立文,邓新立,王海,任军伟.中性粒细胞碱性磷酸酶在传染性非典型肺炎诊断与鉴别诊断中的价值[J].中华检验医学杂志,2005,28(1):34-36. 被引量:14
  • 2宋君红,李建勇,张苏江.骨髓增殖性疾病JAK2基因V617F点突变研究[J].中华血液学杂志,2006,27(9):632-633. 被引量:18
  • 3CAMPBELL P J, BAXTER E J, BEER P A, et al. Mutation of JAK2 in the myelop roliferative disorders: timing, clonality studies, cytogenetic associations and role in leukemic transformation[J]. Blood, 2006,108 3548--3555.
  • 4ROSSI D, DEAMBROGI C, CAPELLO D, et al. JAK2V617F mutation in leukaemic transformation of philadelphia negative chronic myeloproliferative disorders[J]. Blood (ASH Annual Meeting Abstracts), 2006,108 : 3605-- 3605.
  • 5VILLEVAL J L,JAMES C,PISANI D F,et al. New insights into the pathogenesis of JAK2 V617F-posirive myeloproliferative disorders and consequences for the management of patients[J]. Serm Thromh Haemost,2006,32:341--351.
  • 6LIPPERT E, BOISSINOT M, KRALOVICS R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients withessential thrombocythemia and polyeythemia vera[J]. Blood, 2006, 108: 1865- 1867.
  • 7PARDANANI A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials[J].Leukemia, 2008,22:23 --30.
  • 8JOHN M G,JUNIA V M. Chronic myeloid leukemiaadvances in biology and new approaches to treatment[J]. N Engl J Med,2003,349:1451--1464.
  • 9KRALOVICS R, PASSAMONTI F, BUSER A S, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders[J]. N Engl J Med, 2005,352 : 1779 --1790.
  • 10LEVINE R L, WADLEIGH M. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera,essential thrombocythemia and myeloid metaplasia with myetofibrosis[J]. Cancer Cell, 2005,7 : 387-- 397.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部